Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
While this led to successful ADC product approvals, it became clear that the resulting narrow therapeutic windows hampered the use of the modality for broader targets and indications. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.
Let's personalize your content